Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




High HbA1c Levels Linked to Pregnancy Risks

By LabMedica International staff writers
Posted on 08 May 2019
For pregnant women with diabetes mellitus some particular challenges exist for both mother and child. More...
If the woman has diabetes as an intercurrent disease in pregnancy, it can cause early labor, birth defects, and larger than average infants.

High blood sugar levels are harmful to the mother and her fetus. Experts advise diabetics to maintain blood sugar level close to normal range for two to three months before planning for pregnancy. Managing blood sugar close to normal before and during pregnancy helps to protect the health of mother and the baby.

Maternal type 1 diabetes (T1D) has been linked to preterm birth and other adverse pregnancy outcomes. Scientists at the Karolinska Institute (Solna, Sweden) and their associates examined how these risks vary with glycated hemoglobin (or HbA1c) levels. They examined preterm birth risk according to periconceptional HbA1c levels in women with T1D. In a population-based cohort study carried out from 2003 to 2014 and they followed 2,474 singletons born to women with T1D and 1,165,216 reference infants born to women without diabetes. Measurement for the study included risk for preterm birth (<37 gestational weeks), secondary outcomes were neonatal death, large for gestational age, macrosomia, infant birth injury, hypoglycemia, respiratory distress, 5-minute Apgar score less than 7, and stillbirth.

The investigators reported that preterm birth occurred in 552 (22.3%) of 2,474 infants born to mothers with T1D versus 54,287 (4.7%) in the infants born to mothers without diabetes. The incidence of preterm birth was 13.2% in women with a periconceptional HbA1c level below 6.5% (adjusted risk ratio [aRR] versus women without T1D, 2.83), 20.6% in those with a level from 6.5% to less than 7.8% (aRR, 4.22), 28.3% in those with a level from 7.8% to less than 9.1% (aRR, 5.56) and 37.5% in those with a level of 9.1% or higher (aRR, 6.91). The corresponding aRRs for 320 medically indicated preterm birth were 5.26, 7.42, 11.75, and 17.51, respectively. The corresponding aRRs for 223 spontaneous preterm birth were 1.81, 2.86, 2.88, and 2.80, respectively.

Increasing HbA1c levels were associated with the study's secondary outcomes: large for gestational age, hypoglycemia, respiratory distress, low Apgar score, neonatal death, and stillbirth. Jonas F. Ludvigsson, MD, PhD, a professor of pediatrics and lead author of the study, said, “This is the first study large enough to demonstrate a clear relationship between different hemoglobin A1C (Hb A1C) levels and preterm birth. Our study has been conducted nationally and thus provides a result that can be applied to the average woman with type 1 diabetes.” The study was published on April 23, 2019, in the journal Annals of Internal Medicine.

Related Links:
Karolinska Institute


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: Powered by OptraSCAN’s patented OS‑SiA technology, the platform performs scanning, indexing, and AI‑driven analysis simultaneously (Photo courtesy of OptraSCAN)

New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow

Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. Yet consistent, repeatable bacillary assessment... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.